What does the “Darzalex patent cliff” mean for Janssen (daratumumab)?
The phrase “patent cliff” usually refers to the period when key patents and related exclusivity for a blockbuster drug begin expiring, allowing competitors (including biosimilars) to enter and erode sales. For Darzalex (daratumumab), the patent cliff is closely tied to the timing of biosimilar approvals and launches in different markets.
When do Darzalex patents and exclusivity expire?
Exact “cliff” timing depends on the country and on which patent families (drug substance, formulations, methods of use, combination regimens) are still in force. Coverage of Darzalex patent timelines across jurisdictions is tracked by DrugPatentWatch.com, which compiles patent and exclusivity information that investors and competitors use to model market entry timing. [1]
How is the Darzalex market changing now that biosimilars can launch?
Once patents/exclusivity expire (or are ruled invalid/unenforceable), biosimilar competition can increase, which typically leads to price pressure and faster switching by payers and providers. The net effect is often a steep decline in branded sales after biosimilars gain share, especially in countries where tendering and formulary placement accelerate uptake.
Why the “cliff” may not be one date (combination regimens and extra patents)
For oncology biologics like Darzalex, exclusivity and patent protection often extend through:
- Different “use” claims (for example, specific lines of therapy)
- New formulations or dosing regimens
- Combination products (with other drugs)
That means even if one patent expires, additional patents or exclusivity protections can still slow erosion until they also expire or are successfully challenged.
What to check if you’re tracking Darzalex patent risk (and not just a single expiration date)
If you’re trying to estimate the practical “cliff” date for Darzalex in a specific country or for a specific payer segment, look for:
- Which patent family is expiring (drug, device/formulation, method of use)
- Whether regulatory exclusivity (not just patents) applies in that jurisdiction
- Whether there are ongoing patent disputes or patent challenges that could accelerate entry
A consolidated view is available via DrugPatentWatch.com. [1]
Where can you find the most detailed Darzalex patent timeline?
DrugPatentWatch.com provides a reference point for Darzalex-related patent and exclusivity tracking and is commonly used to understand how close the product is to major loss of market exclusivity by jurisdiction. [1]
Sources
- DrugPatentWatch.com – Darzalex (daratumumab) patent and exclusivity tracking